AgenusAGEN
Recorded

Agenus Fireside chat

Review the key takeaways and the transcript of this earnings call.

Period 0Duration54 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael KingAnalyst

All right. It looks like we've got the whole crowd here, so we're going to kick this off.

Michael KingAnalyst

Hello. Yeah. Good morning, everyone.

Michael KingAnalyst

Thanks for joining us here today to speak with the members of the management team of Agenus, symbols AGEN. It's a company that we've had a longstanding relationship with. With us today are Zack Armen, the VP of Corporate Development and Investor Relations, along with Robin Taylor, the Chief Commercial Officer. We're going to discuss the prospect for the company's immuno-oncology duo, known as BOT/BAL, and the imminent phase III study commencement of a phase III trial known as ROBIN. Before we get started, I just want to tell everybody that they were able to ask questions of our audience here by emailing me directly. I would not put them in the chat. I will ask your questions anonymously if you do that. My email address is mking@rodm.com.

Michael KingAnalyst

Just by way of background, we initiated coverage of AGEN at the end of September, rate the shares a buy with a $19 12-month price target. If you would like our report, please feel free to reach out. Full disclosure, neither I nor any member of my household owns the shares, neither are we officer or director of the company. One of the things I say in the report, and I'm quoting myself here, is, "We are hard-pressed to name any other clinical stage oncology asset that has created this large of a dataset prior to the commencement of a registration-directed study." This number may be obsolete now, Zack, you'll correct me, I'm sure, at 1,300 patients in clinical trials alone. I apologize if I stole your thunder here a little bit, but I think it's a remarkable achievement.

Michael KingAnalyst

I think it's unprecedented in the world of immuno-oncology. As such, we have a high degree of confidence in the ultimate outcome of ROBIN, as well as the commercial uptake of the BOT/BAL combination. The way we're going to do this is Zack and Robin will provide us with a slide presentation, and I will ask questions mainly at the end, although fair warning, I've been known to interject from time to time. Gentlemen, thanks for joining us. It's good to have you here. Zack, let me turn it over to you, and I think I need to just allow you to share.

Zack ArmenVP of Corporate Development and Investor Relations

Yeah. Thank you, Mike. And there you go.

Zack ArmenVP of Corporate Development and Investor Relations

Thanks, Mike. We appreciate you and the Rodman & Renshaw team inviting us to the chat. We are obviously very happy that you and your research team are now part of the story here with us as part of the coverage group for our stock. I will just do a quick intro, and Robin will as well, and then Mike, as far as format goes, we actually put together some publicly disseminated slides that go along with your questions.

Zack ArmenVP of Corporate Development and Investor Relations

Okay. Just so this can be a flowing dialogue.

Zack ArmenVP of Corporate Development and Investor Relations

Yeah. Go ahead and ask your questions.

Zack ArmenVP of Corporate Development and Investor Relations

We are going to respond to them with voiceover, and we will have some slides to help enhance those responses.

Michael KingAnalyst

Okay, great. Did you want to introduce yourselves first?

Michael KingAnalyst

Yeah. Then we will. Sure.

Zack ArmenVP of Corporate Development and Investor Relations

Okay, go ahead. My name is Zack Armen.

Zack ArmenVP of Corporate Development and Investor Relations

I am the Head of Corporate Development here at Agenus, and Investor Relations. My role spans both IR, along with capital formation, internal and strategic finance, and business development. Robin and I work very closely across all of those fronts. Our story has drastically changed over the last few months, as we will get into with our July PIPE and our initiation of the new phase III ROBIN trial. To your earlier point, you are not stealing our thunder. We are still at around 1,300 patients treated, although we are planning to treat many more patients starting when we do our first enrollment for the ROBIN trial, which we anticipate in the next few months.

Robin TaylorChief Commercial Officer

Okay, great. I am Robin Taylor.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day